Brief Reports
Copyright ©The Author(s) 2005.
World J Gastroenterol. Aug 21, 2005; 11(31): 4899-4903
Published online Aug 21, 2005. doi: 10.3748/wjg.v11.i31.4899
Figure 1
Figure 1 Schematic representation of B3scdsFv-SEA-pET22b expression plasmid. L: polypeptide linker; L1: (GlyGlyGlyGlySer)3; L2: (GlyGlyGlySer-GlyGlySer).
Figure 2
Figure 2 The SDS-PAGE analysis of expression products (A) and Western blot of inclusion body (B). A: Lane 1: B3scdsFv-SEA- pET22b before induction; lane 2: total protein after induction; lane 3: ultrasonic supernatant of B3scdsFv-SEA-pET22b induced by 1 mmol/L IPTG; lane 4: ultrasonic deposit after induction; lane M: low molecular weight protein marker; B: Lane 1: Western blot of B3scdsFv-SEA; lane 2: negative control (total protein before induction); lane M: low molecular weight protein marker.
Figure 3
Figure 3 Gel mobility of B3scdsFv-SEA under reducing (lane 1) and non-reducing condition (lane 2).
Figure 4
Figure 4 Binding assay of B3scdsFv-SEA to B3 antigen positive carcinoma cell lines.
Figure 5
Figure 5 Stability of B3scdsFv-SEA.
Figure 6
Figure 6 Cytotoxic effects of B3scdsFv-SEA on HT-29 cell line.